APLS - Apellis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.19
+0.16 (+0.55%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close29.03
Open29.15
Bid0.00 x 800
Ask29.18 x 800
Day's Range28.92 - 30.16
52 Week Range12.16 - 33.18
Volume607,083
Avg. Volume606,896
Market Cap1.865B
Beta (3Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)-3.48
Earnings DateNov 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.14
  • GlobeNewswire

    Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week

    Apellis Pharmaceuticals, Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced positive preliminary results in the C3 glomerulopathy (C3G) cohort of the Phase 2 DISCOVERY study. In the data presented on six C3G patients treated with APL-2, there was a downward trend in mean proteinuria as measured by the urine protein-to-creatinine ratio (uPCR). Mean (SE) uPCR decreased from 2.03 (0.46) mg/mg to 1.05 (0.23) mg/mg at study day 84 (normal range

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that on August 6, 2019, the Company approved the grant of an equity award to a new employee with a grant date of November 1, 2019 as an equity inducement award outside of the Company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received an option to purchase 24,600 shares of Apellis common stock.

  • GlobeNewswire

    Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results

    Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed $220 Million Offering of Convertible Senior.

  • Is Apellis Pharmaceuticals, Inc. (APLS) Going to Burn These Hedge Funds?
    Insider Monkey

    Is Apellis Pharmaceuticals, Inc. (APLS) Going to Burn These Hedge Funds?

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]

  • Alexion makes $930M acquisition in bid to bolster blockbuster drug
    American City Business Journals

    Alexion makes $930M acquisition in bid to bolster blockbuster drug

    Alexion says it will acquire clinical-stage startup Achillion Pharmaceuticals Inc. for $930 million upfront.

  • GlobeNewswire

    Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019

    Apellis Pharmaceuticals Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that preliminary clinical data evaluating APL-2 (pegcetacoplan) in complement 3 glomerulopathy (C3G) will be presented at the American Society of Nephrology (ASN) Kidney Week 2019 in Washington D.C. from Nov. 5 - 10. Data from eight patients in the C3G cohort of the Phase 2 DISCOVERY trial of APL-2 will be presented through study day 84 (12 weeks). The DISCOVERY trial is an open-label trial investigating the safety and biological activity of APL-2 in four renal diseases: C3G, immunoglobulin A (IgA) nephropathy, primary membranous nephropathy, and lupus nephritis.

  • Apellis Pharmaceuticals (APLS) Catches Eye: Stock Jumps 5.2%
    Zacks

    Apellis Pharmaceuticals (APLS) Catches Eye: Stock Jumps 5.2%

    Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • GlobeNewswire

    Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 11:15 a.m. ET in New York, NY. The presentation will be given by Cedric Francois, M.D., Ph.D., founder and chief executive officer of Apellis, and will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the Company’s website at http://investors.apellis.com/events-and-presentations. Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3.

  • GlobeNewswire

    Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced details about its Phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) have been published in Ophthalmology, the journal of the American Academy of Ophthalmology. Publication of the full study report follows the release of topline study results earlier this year and shows that treatment with APL-2 resulted in statistically significant reductions in the growth of GA lesion area compared to sham at month 12.

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes

    Apellis Pharmaceuticals, Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its offering of $220.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “notes”). Apellis also granted to the initial purchasers of the notes a 13-day option to purchase up to an additional $33.0 million aggregate principal amount of the notes, solely to cover over-allotments, if any. Subject to certain conditions, on or after September 20, 2023, Apellis may redeem for cash all or a portion of the notes at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, if the last reported sale price of Apellis common stock has been at least 130% of the conversion price then in effect for a specified period of time ending on the trading day immediately before the date the notice of redemption is sent.

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes

    Apellis Pharmaceuticals, Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its offering of $220.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “notes”). Apellis also granted to the initial purchasers of the notes a 13-day option to purchase up to an additional $33.0 million aggregate principal amount of the notes, solely to cover over-allotments, if any. Subject to certain conditions, on or after September 20, 2023, Apellis may redeem for cash all or a portion of the notes at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, if the last reported sale price of Apellis common stock has been at least 130% of the conversion price then in effect for a specified period of time ending on the trading day immediately before the date the notice of redemption is sent.

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

    Apellis Pharmaceuticals, Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Apellis also expects to grant to the initial purchasers of the notes a 13-day option to purchase up to an additional $30 million aggregate principal amount of the notes, solely to cover over-allotments, if any.

  • GlobeNewswire

    Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

    CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 03, 2019 -- Apellis Pharmaceuticals Inc. (NASDAQ: APLS) announced today the dosing of the first patient in the Phase 3 clinical study.

  • GlobeNewswire

    Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

    CRESTWOOD, Ky. and WALTHAM Mass., Aug. 28, 2019 -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel.

  • Should Amgen Finally Buy Alexion Pharmaceuticals?
    Motley Fool

    Should Amgen Finally Buy Alexion Pharmaceuticals?

    One of biotech's longest-running buyout rumors is picking up steam again.

  • GlobeNewswire

    Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results

    Completed Enrollment in Phase 3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Head-to-Head Study in Patients Treated with Eculizumab; Top-line Data Anticipated in December 2019.